BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of “Moderate Buy” by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $19.50.

Several equities research analysts recently weighed in on BCRX shares. Cantor Fitzgerald boosted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. Citizens Jmp reduced their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, November 5th. JMP Securities upped their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a report on Wednesday, October 15th. HC Wainwright raised their target price on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, Needham & Company LLC dropped their target price on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th.

Insider Activity

In other news, insider Alane P. Barnes sold 21,773 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total value of $166,563.45. Following the transaction, the insider directly owned 398,751 shares in the company, valued at approximately $3,050,445.15. The trade was a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 183,453 shares of company stock valued at $1,330,965 over the last 90 days. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BCRX. Family Legacy Financial Solutions LLC acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $72,000. Focus Partners Wealth bought a new position in BioCryst Pharmaceuticals during the third quarter worth $77,000. Farther Finance Advisors LLC raised its stake in BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 8,109 shares during the last quarter. Vestmark Advisory Solutions Inc. bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Up 0.4%

Shares of BCRX opened at $6.78 on Thursday. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -135.60, a price-to-earnings-growth ratio of 0.44 and a beta of 0.80. The company’s fifty day moving average is $7.35 and its 200-day moving average is $7.77. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The business had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. As a group, research analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.